A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH TRASTUZUMAB AND TAXANE

Registry ID

DS8201-A-U302

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

DAIICHI SANKYO INC

Start date

2019-08-29

Completion date

2022-10-03

Last update

2018-12-14

Conditions

• BREAST CANCER HER2-POSITIVE

Related clinical trials

• A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN-LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZANIDATAMAB IN COMBINATION WITH PHYSICIAN¿S CHOICE CHEMOTHERAPY COMPARED TO TRASTUZUMAB IN COMBINATION WITH PHYSICIAN'S CHOICE CHEMOTHERAPY FOR THE TREATMENT OF PARTICIPANTS WITH METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE PROGRESSED ON, OR ARE INTOLERANT TO, PREVIOUS TRASTUZUMAB DERUXTECAN TREATMENT
• A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS
• A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET) (DYNASTY-BREAST02)
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO® VERSUS PLACEBO IN COMBINATION WITH PHESGO® AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA-MUTATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
• DE-ESCALATION OF ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE, ESTROGEN RECEPTOR-NEGATIVE, NODE-NEGATIVE EARLY BREAST CANCER PATIENTS WHO ACHIEVED PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY AND DUAL HER2 BLOCKADE-DECRESCENDO

View on source registry